ES2192018T3 - PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON-GAMMA STIMULATORS. - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON-GAMMA STIMULATORS.

Info

Publication number
ES2192018T3
ES2192018T3 ES99202497T ES99202497T ES2192018T3 ES 2192018 T3 ES2192018 T3 ES 2192018T3 ES 99202497 T ES99202497 T ES 99202497T ES 99202497 T ES99202497 T ES 99202497T ES 2192018 T3 ES2192018 T3 ES 2192018T3
Authority
ES
Spain
Prior art keywords
stimulators
gamma
pharmaceutical composition
composition containing
containing interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99202497T
Other languages
Spanish (es)
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of ES2192018T3 publication Critical patent/ES2192018T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention provides compositions for promoting the healing of chronic wounds comprising stimulators of IFN- gamma .
ES99202497T 1995-08-18 1996-08-09 PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON-GAMMA STIMULATORS. Expired - Lifetime ES2192018T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
ES2192018T3 true ES2192018T3 (en) 2003-09-16

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99202497T Expired - Lifetime ES2192018T3 (en) 1995-08-18 1996-08-09 PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON-GAMMA STIMULATORS.
ES96927141T Expired - Lifetime ES2164911T3 (en) 1995-08-18 1996-08-09 PHARMACEUTICAL COMPOSITION CONTAINING GAMMA INTERFER INHIBITORS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96927141T Expired - Lifetime ES2164911T3 (en) 1995-08-18 1996-08-09 PHARMACEUTICAL COMPOSITION CONTAINING GAMMA INTERFER INHIBITORS.

Country Status (13)

Country Link
EP (2) EP0845007B1 (en)
JP (2) JP4070809B2 (en)
AT (2) ATE231728T1 (en)
AU (1) AU713809B2 (en)
CA (1) CA2229590C (en)
DE (2) DE69626050T2 (en)
DK (2) DK0972521T3 (en)
ES (2) ES2192018T3 (en)
GB (1) GB2304342A (en)
HK (1) HK1023516A1 (en)
PT (2) PT972521E (en)
WO (1) WO1997007136A2 (en)
ZA (1) ZA966953B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2251248T3 (en) 1998-12-09 2006-04-16 Protein Design Labs, Inc. USE OF ANTIBODIES AGAINST IL-12 TO TREAT PSORIASIS.
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
JP2003500113A (en) * 1999-05-26 2003-01-07 ザ ブリガム アンド ウイミンズ ホスピタル、 インコーポレイテッド Therapeutic use of drugs that modulate alpha smooth muscle actin activity
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
JP5530635B2 (en) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 Intestinal adhesion inhibitor
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (en) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Pharmaceutical composition for treating trophic ulcers and persistent wounds of various origins in form of ointment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0311616B1 (en) * 1986-06-17 1991-09-25 Biogen, Inc. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
NL8700927A (en) * 1987-04-16 1988-11-16 Stichting Rega V Z W ANTI-INTERFERON GAMMA ANTIBODIES; AND THEIR THERAPEUTIC APPLICATION.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
SG43205A1 (en) * 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ATE132191T1 (en) * 1989-04-19 1996-01-15 Hoffmann La Roche DISSOLVABLE INTERFERON-GAMMA RECEPTORS AND METHOD FOR THE PRODUCTION THEREOF
IT1231727B (en) * 1989-08-11 1991-12-21 Enrico Savoldi USEFUL PEPTIDES FOR THE DETERMINATION AND PURIFICATION OF ANTIBODIES INTERFERONE RANGE.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
WO1992014480A1 (en) * 1991-02-22 1992-09-03 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (en) * 1991-07-23 1993-02-16 Stichting Rega V Z W RECOMBINANT DNA MOLECULA FOR THE EXPRESSION OF AN FV FRAGMENT OF AN ANTIBODY.
DE4234380A1 (en) * 1992-10-06 1994-04-07 Schering Ag Use of dopamine agonists to activate gamma interferon production
JPH07508763A (en) * 1992-11-20 1995-09-28 シェリング・コーポレーション Antagonist of human gamma interferon
ES2126094T3 (en) * 1992-12-29 1999-03-16 Genentech Inc TREATMENT OF INFLAMMATORY DISEASE OF THE INTESTINES WITH INTERFERON-GAMMA INHIBITORS.
CA2177471A1 (en) * 1993-12-09 1995-06-15 Michel Aguet Ifn-.gamma.receptor .beta.-chain and derivatives thereof

Also Published As

Publication number Publication date
AU6707196A (en) 1997-03-12
EP0972521B1 (en) 2003-01-29
EP0972521A1 (en) 2000-01-19
JP4616291B2 (en) 2011-01-19
AU713809B2 (en) 1999-12-09
CA2229590C (en) 2010-10-12
DE69626050T2 (en) 2004-01-22
ATE231728T1 (en) 2003-02-15
EP0845007A2 (en) 1998-06-03
ZA966953B (en) 1998-02-16
CA2229590A1 (en) 1997-02-27
PT845007E (en) 2002-03-28
PT972521E (en) 2003-06-30
DE69626050D1 (en) 2003-03-06
DK0845007T3 (en) 2001-12-17
ATE208402T1 (en) 2001-11-15
DK0972521T3 (en) 2003-05-05
HK1023516A1 (en) 2000-09-15
WO1997007136A3 (en) 1997-08-21
EP0845007B1 (en) 2001-11-07
GB2304342A (en) 1997-03-19
GB9516967D0 (en) 1995-10-18
WO1997007136A2 (en) 1997-02-27
JP4070809B2 (en) 2008-04-02
JPH11511160A (en) 1999-09-28
JP2007119497A (en) 2007-05-17
DE69616803D1 (en) 2001-12-13
DE69616803T2 (en) 2002-06-20
ES2164911T3 (en) 2002-03-01

Similar Documents

Publication Publication Date Title
ATE288893T1 (en) POLYMORPHOUS FORM OF ATORVASTATIN CALCIUM
CR9879A (en) CCR5 MODULATORS (APPLICATION DIVISIONAL N ° 6392)
EE03969B1 (en) (Methylsulfonyl) phenyl-2- (5H) -furanones, their Use and Pharmaceutical Compositions
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
EP0458699A3 (en) Use of baclofen for the preparation of medicaments for the treatment of angina pectoris
ES2193919T3 (en) INHIBITORS OF THE ENDOTELINE CONVERTER ENZYME.
ES2192018T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON-GAMMA STIMULATORS.
ATE235245T1 (en) PHARMACEUTICAL COMPOSITION
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
ATE107859T1 (en) USE OF ANTIPROGESTOMIMETICS TO STIMULATE OVULATION.
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
IT1270905B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCARNOSINE FOR THE TREATMENT OF CATARACT
ES2150418T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING CALCITONIN.
IT1265647B1 (en) TOPICAL PHARMACEUTICAL COMPOSITION FOR RESPIRATORY ALLERGIES
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
UA23873A (en) Medicinal composition for treatment and prophylaxis (variants)
DK1260222T3 (en) Pharmaceutical compositions containing novel iso-butenyl-substituted taxanes
ECSP993296A (en) CCR5 MODULATORS
ECSP993298A (en) CCR5 MODULATORS